Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 3076 AL 3090

Atypical Presentation of Covid-19 in an Older Adult With Severe Alzheimer Disease

Isaia G, Marinello R, Tibaldi V, Tamone C, Bo M.

Am J Geriatr Psychiatry. 2020 Jul;28(7):790-791. doi: 10.1016/j.jagp.2020.04.018. Epub 2020 Apr 22.

Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery

Hampel H, Vergallo A, Caraci F, Cuello AC, Lemercier P, Vellas B, Giudici KV, Baldacci F, Hänisch B, Haberkamp M, Broich K, Nisticò R, Emanuele E, Llavero F, Zugaza JL, Lucía A, Giacobini E, Lista S; Alzheimer Precision Medicine Initiative.

Neuropharmacology. 2021 Mar 1;185:108081. doi: 10.1016/j.neuropharm.2020.108081. Epub 2020 May 11.

Neurobiologic Rationale for Treatment of Apathy in Alzheimer's Disease With Methylphenidate

van Dyck CH, Arnsten AFT, Padala PR, Brawman-Mintzer O, Lerner AJ, Porsteinsson AP, Scherer RW, Levey AI, Herrmann N, Jamil N, Mintzer JE, Lanctôt KL, Rosenberg PB.

Am J Geriatr Psychiatry. 2021 Jan;29(1):51-62. doi: 10.1016/j.jagp.2020.04.026. Epub 2020 May 5.

Evidence on the New Drug Lumateperone (ITI-007) for Psychiatric and Neurological Disorders

Mazza M, Marano G, Traversi G, Sani G, Janiri L.

CNS Neurol Disord Drug Targets. 2020;19(4):243-247. doi: 10.2174/1871527319666200601145653.

The effect of physical activity on cognition relative to APOE genotype (PAAD-2): study protocol for a phase II randomized control trial

Park KS, Ganesh AB, Berry NT, Mobley YP, Karper WB, Labban JD, Wahlheim CN, Williams TM, Wideman L, Etnier JL.

BMC Neurol. 2020 Jun 6;20(1):231. doi: 10.1186/s12883-020-01732-1.

Effects of Citicoline as an Adjunct Treatment for Alzheimer's Disease: A Systematic Review

Piamonte BLC, Espiritu AI, Anlacan VMM.

J Alzheimers Dis. 2020;76(2):725-732. doi: 10.3233/JAD-200378.

The Efficacy of Sertraline, Escitalopram, and Nicergoline in the Treatment of Depression and Apathy in Alzheimer's Disease: The Okayama Depression and Apathy Project (ODAP)

Takemoto M, Ohta Y, Hishikawa N, Yamashita T, Nomura E, Tsunoda K, Sasaki R, Tadokoro K, Matsumoto N, Omote Y, Abe K.

J Alzheimers Dis. 2020;76(2):769-772. doi: 10.3233/JAD-200247.

Meta-analysis of Ginkgo biloba Preparation for the Treatment of Alzheimer's Disease

Liao Z, Cheng L, Li X, Zhang M, Wang S, Huo R.

Clin Neuropharmacol. 2020 Jul/Aug;43(4):93-99. doi: 10.1097/WNF.0000000000000394.

Calcium Channel Blockers: A Possible Potential Therapeutic Strategy for the Treatment of Alzheimer's Dementia Patients with SARS-CoV-2 Infection

Danta CC.

ACS Chem Neurosci. 2020 Aug 5;11(15):2145-2148. doi: 10.1021/acschemneuro.0c00391. Epub 2020 Jul 14.

Quinones as preventive agents in Alzheimer's diseases: focus on NLRP3 inflammasomes

Chen DB, Gao HW, Peng C, Pei SQ, Dai AR, Yu XT, Zhou P, Wang Y, Cai B.

J Pharm Pharmacol. 2020 Nov;72(11):1481-1490. doi: 10.1111/jphp.13332. Epub 2020 Jul 15.

Effect of Rotigotine vs Placebo on Cognitive Functions Among Patients With Mild to Moderate Alzheimer Disease: A Randomized Clinical Trial

Koch G, Motta C, Bonnì S, Pellicciari MC, Picazio S, Casula EP, Maiella M, Di Lorenzo F, Ponzo V, Ferrari C, Scaricamazza E, Caltagirone C, Martorana A.

JAMA Netw Open. 2020 Jul 1;3(7):e2010372. doi: 10.1001/jamanetworkopen.2020.10372.

Could Self-Consciousness Be Enhanced in Alzheimer's Disease? An Approach from Emotional Sensorial Stimulation

Arroyo-Anlló EM, Sánchez JC, Gil R.

J Alzheimers Dis. 2020;77(2):505-521. doi: 10.3233/JAD-200408.

Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial

Arellanes IC, Choe N, Solomon V, He X, Kavin B, Martinez AE, Kono N, Buennagel DP, Hazra N, Kim G, D'Orazio LM, McCleary C, Sagare A, Zlokovic BV, Hodis HN, Mack WJ, Chui HC, Harrington MG, Braskie MN, Schneider LS, Yassine HN.

EBioMedicine. 2020 Sep;59:102883. doi: 10.1016/j.ebiom.2020.102883. Epub 2020 Jul 17.

Safety and target engagement profile of two oxaloacetate doses in Alzheimer's patients

Vidoni ED, Choi IY, Lee P, Reed G, Zhang N, Pleen J, Mahnken JD, Clutton J, Becker A, Sherry E, Bothwell R, Anderson H, Harris RA, Brooks W, Wilkins HM, Mosconi L, Burns JM, Swerdlow RH.

Alzheimers Dement. 2021 Jan;17(1):7-17. doi: 10.1002/alz.12156. Epub 2020 Jul 27.

Health Outcome Prioritization in Alzheimer's Disease: Understanding the Ethical Landscape

McKeown A, Turner A, Angehrn Z, Gove D, Ly A, Nordon C, Nelson M, Tochel C, Mittelstadt B, Keenan A, Smith M, Singh I.

J Alzheimers Dis. 2020;77(1):339-353. doi: 10.3233/JAD-191300.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias